the aid library

Filter

890

Country Profile on Yellow Fever: Argentina

World Health Organisation (WHO) (2022) C_WHO

This country profile presents a summary and analysis of Argentina's status with yellow fever. It is part of a series of profiles on this topic, each focusing on a different country in the Region of the Americas. Argentina's geographical location pre ... more

The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study

Mortimer, K.; Lesosky, M.; García-Marcos, L.; et al. (2022) CC2

Asthma, hay fever and eczema are three common chronic conditions. There have been no recent multi-country data on the burden of these three conditions ... more

Maldives National Action Plan for Containment of Antimicrobial Resistance 2017-2022

Maldives Food and Drug Authority Ministry of Health (2017) C2

Maldives has made significant strides in the area of infectious disease prevention and control. This is exemplified by elimination of malaria from Maldives in 2015 and successes in TB control. In addition, Maldives is a front runner in infectious disease prevention through successful water, sanitati ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Fever Diagnostic Technology Landscape
recommended

UNITAID World Health Organisation (WHO) (2018) C_WHO

1st edition. Unitaid’s report describes a slate of new devices that can more efficiently identify dangerously ill children so that they can be treated immediately. These tools make it easier to recognize danger signs, and support integrated approaches to reducing childhood deaths from the three ... more

Communication and social mobilization in yellow fever mass vaccination campaigns

World Health Organization WHO (2015) C_WHO

10 points from field experience

Operational guidance on the use of yellow fever assays in the context of surveillance

World Health Organization WHO (2023) C_WHO

This publication aims to provide updated guidance on the specific use of yellow fever laboratory assays in the context of surveillance to be used across the Global Yellow Fever Laboratory Network fo ... more

Clinical Management of Yellow Fever in the Region of the Americas. Experiences and Recommendations for Health Services

Pan American Health Organisation PAHO (2023) C_WHO

The waves of yellow fever transmission in the Region of the Americas in 2016–2018 involved the largest number of human and epizootic cases to be reported in several decades. Yellow fever is a seri ... more

Liberia Media Kit: Priority Diseases and Conditions

Ministry of Health and Social Welfare, Liberia; World Health Organization (WHO) (2017) C_WHO

Guidelines for the Management of Typhoid Fever
recommended

Ministry of Health and Child Welfare,Zimbabwe; WHO; European Commission Humanitarian Aid (2011) C_WHO

Clinical management of patients with viral haemorrhagic fever. A pocket guide for the front-line health worker
recommended

World Health Organization, Regional Office for Africa; (2016) C_WHO

The purpose of this pocketbook is to provide clear guidance on current best management practices for VHF across health-care facilities

Information for Healthcare Providers Chikungunya Fever

Pan American Health Organization; World Health Organization Regional (2014) C_WHO

Fact Sheet

Risk assessment on yellow fever virus circulation in endemic countries

World Health Organization WHO (2014) C_WHO

Working document from an informal consultation of experts. A Protocol for risk assessment at the field level. The purpose of document is to provide guidance on the methodology to be used for assessing, at field level, the yellow fever virus circula ... more

Antenatal Guidelines for Primary Health Care in Crisis Conditions

Cristina Otero Garcia ICRC (2005)

These guidelines are designed for ICRC and other health professionals – nurses, midwifes, doctors – who either lack experience in antenatal care or are not used to working in countries where medical infrastructure is underdeveloped or non-existent

Standard treatment guidelines medicine ( Non Respiratory Infectious Medical Conditions) India

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020

Standard Treatment Guidelines and Essential Medicines List of Common Medical Conditions

Government of the Kingdom of Swaziland Ministry of Health (2012) C2

The product of all this work is the Standard Treatment Guideline and Essential Medicines List of Common Medical Conditions in the Kingdom of Swaziland. These systematically developed statements are designed to assist practitioners in making decision ... more

Nigeria: Standard Operating Procedures for Lassa Fever Case Management

Nigeria Centre for Disease Control (2017) C2